To investigate whether FANCD2 is a predictive biomarker for immunotherapy efficacy, we evaluated the relationship between FANCD2 and outcomes by the tumor immune dysfunction and exclusion (TIDE) score (Figure 6E). The gene discussed is FANCD2; the disease is neoplasm.